Home › Compare › HRDIL vs ABBV
HRDIL yields 1000000.00% · ABBV yields 3.06%● Live data
📍 HRDIL pulled ahead of the other in Year 1
Combined, HRDIL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HRDIL + ABBV for your $10,000?
Here Media Inc. offers original programming content tailored for the lesbian, gay, bisexual, and transgender (LGBT) community on a subscription basis. The company publishes magazines and books, as well as operates companion Websites targeting the LGBT community. Its products include the magazines Out, The Advocate, and HIVPlus, as well as books published by Alyson Books, which are distributed through traditional newsstands, other retail outlets, and by subscriptions of print and digital editions of the magazines. It also operates PlanetOut, an online media company serving the LGBT community through its website Gay.com, a social networking Website; and a companion Website, heretv.com that features original shows, podcasts, news, and other entertainment, as well as a library of LGBT-themed streaming video. In addition, the company provides subscription video-on-demand and/or regularly scheduled television channel services through cable, satellite, and fiber-optic television providers serving domestic television households in the United States; and syndicates free-to-the-user content to Websites, including msn.com and aol.com. It serves customers through cable television, direct-to-home satellite television, fiber-optic television, and the Internet under the brand name "here!". The company is was founded in 2009 and is headquartered in Los Angeles, California.
Full HRDIL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.